Why pre-screen precision medicine researchers before the interview
The majority of variants returned by sequencing cannot be classified confidently, and the pressure to give a clinician something actionable is constant. Researchers worth hiring hold the line: they classify against established criteria, report uncertainty as uncertainty, and can describe a variant they refused to call. A short screen asks for that, which separates interpretation discipline from analytical capability.
What actually matters when screening Precision Medicine Researcher candidates
- 01
Technique and experimental design
Check depth in genomic assays and cohort design: NGS panel versus WES/WGS choices, sample size and power calculations, batch controls, and handling of confounders like ancestry stratification.
- 02
Results that went somewhere
Probe which biomarkers or signatures actually reached a clinical decision: companion diagnostic submissions, trial stratification arms, tumour board input, publications, or IP filed from their work.
- 03
Troubleshooting and reproducibility
Test how they handle failed replication and noisy signals: batch correction in nextflow or Bioconductor pipelines, low-input degraded FFPE samples, VAF artefacts, and overfitted classifiers.
- 04
Documentation and collaboration
Assess documentation and cross-team habits: ACMG or AMP variant classification records, IRB and consent protocols, version-controlled analysis code, and work with clinicians, pathologists, and bioinformaticians.
Pre-screening questions to ask Precision Medicine Researcher candidates
12 questions grouped by what they test. Ask the same set in every screen and score answers on a consistent scale, or send them as an async video screen and compare answers side by side.
Findings that reached patients
3 questions01Can you explain a time when you identified a variant of clinical significance?
Listen forA classification made against established criteria, with the evidence weighed and a second reviewer involved.
Variants classified from a database lookup, or clinical significance asserted without evidence review.
02Can you discuss your experience with clinical trials in this area?
Listen forTrial work with an understanding of enrolment criteria and what a biomarker-selected population changes.
Trial involvement described from a distance, or selection effects on trial results not understood.
03Describe your experience with treatment strategies based on patient genetic profiles.
Listen forRealistic account of where genetic information changes treatment and where the evidence is still thin.
Genetic tailoring presented as broadly established, or the evidence base overstated.
Interpretation by criteria
3 questions04What methods do you use for variant annotation and interpretation?
Listen forEstablished classification criteria applied systematically, with population frequency and functional evidence weighed.
Interpretation by intuition, or prediction tools treated as sufficient evidence for a classification.
05How do you validate the clinical relevance of your findings?
Listen forIndependent evidence sought including functional data and segregation, before anything is reported clinically.
Findings reported on a single line of evidence, or validation left to the receiving clinician.
06Describe your experience with pharmacogenomics and its clinical application.
Listen forEstablished gene and drug pairs distinguished from speculative ones, with guideline evidence levels known.
All pharmacogenomic associations treated as equally actionable, or guideline strength not considered.
Integration done rigorously
4 questions07What experience do you have with genomic data analysis and interpretation?
Listen forAnalysis performed by them with quality control at each stage, including coverage and call confidence.
Pipelines run without inspecting quality metrics, or low coverage regions not flagged in reports.
08How do you approach integrating multiple data types in your research?
Listen forIntegration attempted where it answers a question, with batch and platform effects handled properly.
Data types combined without normalisation, or platform effects mistaken for biological signal.
09What platforms have you used for sequencing data analysis?
Listen forPipelines understood well enough to know what each step assumes and where it fails.
Tools run as a black box, or reference build and version not recorded with results.
10Have you used machine learning models with genetic data?
Listen forAwareness that features vastly outnumber samples, with validation designed to avoid leakage.
Models fitted without regularisation or independent validation, or performance reported in sample.
Patient data protected
2 questions11How do you ensure privacy and security when handling patient genetic data?
Listen forGenetic data treated as identifiable, with access controlled and consent scope respected for secondary use.
Genetic data treated as anonymous, or reuse beyond the original consent not questioned.
12What ethical considerations do you regard as important in this research?
Listen forIncidental findings, family implications and return of results all considered with a clear policy.
Incidental findings not planned for, or family implications of a result never considered.
How to score responses
Score every candidate on the same four criteria immediately after the screen. At this stage you are shortlisting for panel interviews, not making the final call.
Technique and experimental design
35%5Names specific platforms (Illumina NovaSeq, 10x single cell), justifies cohort size with power figures, and controls batch and ancestry effects deliberately.
Results that went somewhere
25%5Points to a signature that changed patient stratification or a validated assay, with the trial, publication, or regulatory pathway attached.
Troubleshooting and reproducibility
25%5Describes a signal that collapsed on an external validation cohort, plus the concrete diagnosis and rebuilt pipeline that followed.
Documentation and collaboration
15%5Keeps reproducible repositories and audit-ready IRB and classification records; works fluently with pathology and clinical trial staff, not just the bench.
Most variants cannot be classified confidently, and the pressure to give an answer is constant. A one-way video screen asks about one they refused to call.
Try it on HirevireScreening FAQ
Process basics
How long should a pre-screening round for this role take?
Fifteen minutes across eight to ten questions, answered async. Enough to establish the findings that reached patients, test their interpretation discipline, and check how they handle patient data.
How much clinical exposure should I expect?
Enough to understand what a clinician will do with a result. A researcher with no clinical contact will report findings in a form that cannot be acted on or that overstates certainty.
Evaluating answers
What is the strongest signal when screening this role?
A variant they refused to classify. Researchers with interpretation discipline have several. Anyone whose findings were all conclusive has been resolving uncertainty in the convenient direction.
How do I judge their interpretation practice?
Ask which criteria they apply. Real answers name an established framework and describe applying it with a second reviewer. Anyone classifying by intuition will produce inconsistent reports.
Go deeper on this role
Sanat has been hiring since 2012 and watching the recruitment industry change up close ever since, and turned that screening process into Hirevire's video screening platform. LinkedIn
